CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2390
-0.0110 (-4.40%)
Feb 9, 2026, 3:59 PM EST
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
304.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | - | - | - |
| May 31, 2024 | - | - | - |
| May 31, 2023 | - | - | - |
| May 31, 2022 | 266.00K | - | - |
| May 31, 2021 | - | - | - |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
CytoDyn News
- 13 days ago - CytoDyn Secures Funding To Launch Expanded Access Program For Leronlimab In Breast Cancer - Nasdaq
- 13 days ago - CytoDyn (CYDY) Secures Funding for Breast Cancer Program - GuruFocus
- 13 days ago - CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer - GlobeNewsWire
- 7 weeks ago - CytoDyn (CYDY) Anticipates Significant Progress in 2026 - GuruFocus
- 7 weeks ago - December 2025 Letter to Shareholders - GlobeNewsWire
- 2 months ago - CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - CytoDyn Announces Resolution of Class Action Lawsuit - GlobeNewsWire
- 2 months ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire